Literature DB >> 3367166

Intravenous natural beta interferon treatment of chronic exacerbating-remitting multiple sclerosis: clinical response and MRI/CSF findings.

M Huber1, S Bamborschke, J Assheuer, W D Heiss.   

Abstract

A preliminary study is reported of clinical response and CSF/MRI findings in nine patients with multiple sclerosis receiving intravenous infusions of natural beta-interferon. The mean patient follow-up was for 1.2 years. Neither exacerbation rates nor CSF-IgG synthesis nor plaque formation as revealed by MRI showed a significant reduction during therapy. One patient developed a severe exacerbation of multiple sclerosis shortly after interferon infusion.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3367166     DOI： 10.1007/bf00314311

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


  7 in total

1.  Therapeutic trials in multiple sclerosis.

Authors:  J H Noseworthy; T P Seland; G C Ebers
Journal:  Can J Neurol Sci       Date:  1984-08       Impact factor: 2.104

2.  Systemic alpha-interferon therapy of multiple sclerosis.

Authors:  R L Knobler; H S Panitch; S L Braheny; J C Sipe; G P Rice; J R Huddlestone; G S Francis; C K Hooper; R M Kamin-Lewis; K P Johnson
Journal:  Neurology       Date:  1984-10       Impact factor: 9.910

3.  New diagnostic criteria for multiple sclerosis: guidelines for research protocols.

Authors:  C M Poser; D W Paty; L Scheinberg; W I McDonald; F A Davis; G C Ebers; K P Johnson; W A Sibley; D H Silberberg; W W Tourtellotte
Journal:  Ann Neurol       Date:  1983-03       Impact factor: 10.422

4.  [Additional examinations for ascertaining the diagnosis of multiple sclerosis].

Authors:  H Bewermeyer; S Bamborschke; J Assheuer; H A Dreesbach; G Buchberger; M Neveling; J K Mai; W D Heiss
Journal:  Dtsch Med Wochenschr       Date:  1986-09-12       Impact factor: 0.628

5.  Serial immunological studies in multiple sclerosis patients treated systemically with human alpha interferon.

Authors:  H S Panitch; G S Francis; C J Hooper; T C Merigan; K P Johnson
Journal:  Ann Neurol       Date:  1985-10       Impact factor: 10.422

6.  Immunological complications in multiple sclerosis patients receiving interferon.

Authors:  G P Rice; E L Woelfel; P J Talbot; S L Braheny; J C Sipe; R L Knobler; T C Merigan; M B Oldstone
Journal:  Ann Neurol       Date:  1985-10       Impact factor: 10.422

7.  Multicentre double-blind study of effect of intrathecally administered natural human fibroblast interferon on exacerbations of multiple sclerosis.

Authors:  L Jacobs; A M Salazar; R Herndon; P A Reese; A Freeman; R Josefowicz; A Cuetter; F Husain; W A Smith; R Ekes
Journal:  Lancet       Date:  1986 Dec 20-27       Impact factor: 79.321
  7 in total
  2 in total

1.  Double blind study of intrathecal beta-interferon in multiple sclerosis: clinical and laboratory results.

Authors:  C Milanese; A Salmaggi; L La Mantia; A Campi; M Eoli; M Savoiardo; G Bianchi; A Nespolo
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-07       Impact factor: 10.154

2.  Prescribing recommendations for interferon-Beta in multiple sclerosis.

Authors:  B Weinstock-Guttman; R A Rudick
Journal:  CNS Drugs       Date:  1997-08       Impact factor: 5.749
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.